These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34876018)

  • 41. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
    Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C.
    Manchiero C; Nunes AKDS; Magri MC; Dantas BP; Mazza CC; Barone AA; Tengan FM
    BMC Infect Dis; 2017 Dec; 17(1):780. PubMed ID: 29258449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
    Liu YL; Reeves HL; Burt AD; Tiniakos D; McPherson S; Leathart JB; Allison ME; Alexander GJ; Piguet AC; Anty R; Donaldson P; Aithal GP; Francque S; Van Gaal L; Clement K; Ratziu V; Dufour JF; Day CP; Daly AK; Anstee QM
    Nat Commun; 2014 Jun; 5():4309. PubMed ID: 24978903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of gene-chronic hepatitis C virus infection on hepatic fibrosis and steatosis.
    Magri MC; Manchiero C; Prata TVG; Nunes AKDS; Oliveira Junior JS; Dantas BP; Tengan FM
    Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115025. PubMed ID: 32147132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Kim NY; Ko JS
    Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease.
    Xue WY; Zhang L; Liu CM; Gao Y; Li SJ; Huai ZY; Dai J; Wang YY
    Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):97-107. PubMed ID: 35057689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.
    Cai G; Zhang B; Shi G; Weng W; Ma C; Song Y; Zhang J
    Lipids Health Dis; 2015 Nov; 14():149. PubMed ID: 26576960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.
    Goffredo M; Caprio S; Feldstein AE; D'Adamo E; Shaw MM; Pierpont B; Savoye M; Zhao H; Bale AE; Santoro N
    Hepatology; 2016 Jan; 63(1):117-25. PubMed ID: 26457389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study.
    Trunečka P; Míková I; Dlouhá D; Hubáček JA; Honsová E; Kolesár L; Lánská V; Fraňková S; Šperl J; Jirsa M; Poledne R
    Dig Liver Dis; 2018 May; 50(5):490-495. PubMed ID: 29396131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
    Grimaudo S; Bartesaghi S; Rametta R; Marra F; Margherita Mancina R; Pihlajamäki J; Kakol-Palm D; Andréasson AC; Dongiovanni P; Ludovica Fracanzani A; Lori G; Männistö V; Pellegrini G; Bohlooly-Y M; Pennisi G; Maria Pipitone R; Spagnuolo R; Craxì A; Lindén D; Valenti L; Romeo S; Petta S
    Liver Int; 2021 Feb; 41(2):321-332. PubMed ID: 33091218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility.
    Xia Y; Huang CX; Li GY; Chen KH; Han L; Tang L; Luo HQ; Bao MH
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):533-541. PubMed ID: 30824369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of PNPLA3 rs738409 and TM6SF2 rs58542926 with health services utilization in a population-based study.
    Köpp J; Fleßa S; Lieb W; Markus MRP; Teumer A; Homuth G; Wallaschofski H; Marschall P; Völzke H; Baumeister SE
    BMC Health Serv Res; 2016 Feb; 16():41. PubMed ID: 26847197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome.
    Xavier LB; Sóter MO; Sales MF; Oliveira DK; Reis HJ; Candido AL; Reis FM; Silva IO; Gomes KB; Ferreira CN
    Gene; 2018 Feb; 644():129-136. PubMed ID: 29109005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Lebeau PF; Byun JH; Platko K; Al-Hashimi AA; Lhoták Š; MacDonald ME; Mejia-Benitez A; Prat A; Igdoura SA; Trigatti B; Maclean KN; Seidah NG; Austin RC
    JHEP Rep; 2019 Dec; 1(6):418-429. PubMed ID: 32039393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
    Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationships among N,N-dimethylformamide exposure, CYP2E1 and TM6SF2 genes, and non-alcoholic fatty liver disease.
    Zhou Z; Sang L; Wang J; Song L; Zhu L; Wang Y; Xiao J; Lian Y
    Ecotoxicol Environ Saf; 2021 Nov; 228():112986. PubMed ID: 34794021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.